Abstract
Summary Background: Impaired oxidative/antioxidative balance plays an important role in the pathogenesis of many diseases, including cancer. The aim of this study was to evaluate the levels of the novel marker ischemia modified albumin (IMA) and albumin adjusted-IMA (Adj-IMA) in patients with multi- ple myeloma (MM) as well as its association with total antiox- idant status (TAS), total oxidant status (TOS) and oxidative stress index (OSI). Methods: Forty patients with MM (18 females, 22 males; mean age 67.55±8.39 years) and forty age/sex-matched healthy persons (19 females, 21 males; mean age 66.37 ± 6.76 years) were included in this study. Serum levels of IMA, TAS, TOS were analyzed and Adj-IMA and OSI was calcu- lated. Results: Serum IMA, TOS and OSI levels were significantly higher in patients with MM compared to controls (p<0.001 all parameters). There was no significant difference for serum albumin-adjusted IMA and TAS levels between groups (p=0.83 and p=0.17 respectively). Conclusions: In this study, an impaired oxidative/antioxidant status in favor of oxidative stress was found in MM patients. This observation was not confirmed by Adj-IMA calculation. Further studies are needed to establish the relationship of IMA and oxidative stress parameters in multiple myeloma and their relationship to MM and other cancers.
Highlights
Multiple myeloma (MM) is a cancer of the plasma cells
The aim of this study was to evaluate the levels of the novel marker ischemia modified albumin (IMA) and albumin adjusted-IMA (Adj-IMA) in patients with multiple myeloma (MM) as well as its association with total antioxidant status (TAS), total oxidant status (TOS) and oxidative stress index (OSI)
There was no significant difference for serum albumin-adjusted IMA and TAS levels between groups (p=0.83 and p=0.17 respectively)
Summary
Multiple myeloma (MM) is a cancer of the plasma cells. It is the second most frequent malignancy of the blood in the USA after non-Hodgkin’s lymphoma, accounting for 1% of neoplastic diseases and 13% of hematological malignancies. Clonal enlargement of the tumor cells results in the excessive generation of monoclonal immunoglobulin (Ig), which is a diagnostic property of this disease. Collection of monoclonal Ig light chains in the kidneys can lead to renal failure, which is usually shown in MM. A different feature of MM is the accumulation of malignant cells in the bone marrow, where they lead to osteolytic bone devastation and impaired hematopoiesis [1, 2]. The etiology of multiple myeloma (MM) is unknown, but one of the suspects is the oxidative stress, as is the case in many other malignant diseases
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
